Akari Therapeutics FY2023 net loss narrows to $10M; all-stock merger with Peak Bio

Akari Therapeutics Plc

2024-Q1 EPS reported $0.00

FY2023 net loss $10.0M vs $17.7M in 2022; cash $3.8M at year-end, raised $2.0M in March 2024.
Merger as equals with Peak Bio in all-stock transaction; combined pipeline includes ADC, NEI, nomacopan, PAS-nomacopan.
Nomacopan Phase 3 for pediatric HSCT-TMA ongoing: 10 patients treated; orphan drug and rare pediatric disease designations.
R&D expenses $5.5M (down 43% YoY); G&A $11.4M (down 16% YoY); additional capital planned Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Akari Therapeutics Plc reported the full year ended December 31, 2023 results: net income Net loss was approximately $10.0 million for the year ended December 31, 2023.

Period: the full year ended December 31, 2023
Net income: Net loss was approximately $10.0 million for the year ended December 31, 2023
Result: reported results

Exact text from the filing

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Akari Therapeutics Plc filing history →

Source: SEC EDGAR

accession 0000950170-24-038854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.